Enzo Biochem, Inc. Annual report pursuant to Section 13 and 15(d)

Segment reporting (Tables)

12 Months Ended

Jul. 31, 2020

	Clinical Laboratory Services			Life Sciences Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	47,964		$	26,561		—			—		$	74,525
Grant income		1,496			—		—			—			1,496
Total		49,460			26,561		—			—			76,021
Operating costs and expenses::
Cost of revenues		38,855			13,396		—			—			52,251
Research and development		1,509			2,190	$	749			—			4,448
Selling, general and administrative		23,533			10,485		—		$	8,942			42,960
Legal and related expenses		211			2		—			6,516			6,729
Total operating costs and expenses		64,108			26,073		749			15,458			106,388

Operating (loss) income		(14,648	)		488		(749	)		(15,458	)		(30,367	)

Other income (expense)
Interest		(36	)		56		—			434			454
Other		45			13		—			430			488
Foreign exchange gain		—			905		—			—			905
(Loss) income before taxes	$	(14,639	)	$	1,462	$	(749	)	$	(14,594	)	$	(28,520	)

Depreciation and amortization included above	$	1,553		$	964		—		$	263		$	2,780

Share-based compensation included above:
Selling, general and administrative		57			74		—			756			887
Cost of sales		46			—		—			—			46
Total	$	103		$	74		—		$	756		$	933

Capital expenditures	$	1,811		$	322		—		$	37		$	2,170

	Clinical Laboratory Services			Life Sciences Products			Therapeutics			Other			Consolidated
Revenues	$	51,115		$	30,055		$	—		$	—		$	81,170
Operating costs, expenses and legal settlements, net:
Cost of revenues		44,226			13,696			—			—			57,922
Research and development		31			2,257			887			—			3,175
Selling, general and administrative		24,230			11,860			—			8,175			44,265
Legal and related expenses		159			27			—			2,814			3,000
Legal settlements, net		—			(28,925	)		—			—			(28,925	)
Total operating costs, expenses and legal settlements, net		68,646			(1,085	)		887			10,989			79,437

Operating income (loss)		(17,531	)		31,140			(887	)		(10,989	)		1,733

Other income (expense)
Interest		(64	)		67			—			1,053			1,056
Other		16			2			—			364			382
Foreign exchange loss		—			(682	)		—			—			(682	)
Income (loss) before taxes	$	(17,579	)	$	30,527		$	(887	)	$	(9,572	)	$	2,489

Depreciation and amortization included above	$	1,625		$	1,221		$	—		$	190		$	3,036

Share-based compensation included above:
Selling, general and administrative		147			95			—		$	697			939
Total	$	147		$	95		$	—		$	697		$	939

Capital expenditures	$	1,374		$	605		$	—		$	6,147		$	8,126

	Clinical Laboratory Services			Life Sciences Products			Therapeutics			Other			Consolidated
Revenues	$	71,077		$	29,936		$	—		$	—		$	101,013
Operating costs and expenses:
Cost of revenues		46,008			14,377			—			—			60,385
Research and development		—			2,305			905			—			3,210
Selling, general and administrative		24,656			11,617			—			8,182			44,455
Legal and related expenses		67			58			—			5,002			5,127
Total operating costs and expenses		70,731			28,357			905			13,184			113,177

Operating income (loss)		346			1,579			(905	)		(13,184	)		(12,164	)

Other income (expense)
Interest		(91	)		50			—			894			853
Other		29			11			—			128			168
Foreign exchange loss		—			(275	)		—			—			(275	)
Income (loss) before taxes	$	284		$	1,365		$	(905	)	$	(12,162	)	$	(11,418	)

Depreciation and amortization included above	$	1,667		$	1,387		$	—		$	76		$	3,130

Share-based compensation included in above:
Selling, general and administrative		125			79			—		$	609			813
Total	$	125		$	79		$	—		$	609		$	813

Capital expenditures	$	1,685		$	203		$	—		$	—		$	1,888

Net Services, Products and Grant and royalty revenues from unaffiliated customers, Year ended July 31,:	2020		2019		2018
United States	$	64,040	$	68,081	$	87,296
Switzerland		608		820		829
United Kingdom		1,189		1,642		1,494
Other international countries		10,184		10,627		11,394
Total	$	76,021	$	81,170	$	101,013

Long-lived assets, at July 31,	2020		2019
United States	$	41,946	$	22,057
Switzerland		352		376
United Kingdom		23		64
Other international countries		67		96
Total	$	42,388	$	22,593